Matsumoto, Kazuhiro

写真a

Affiliation

School of Medicine, Department of Urology (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor
Page Top ▲

Career 【 Display / hide 】

  • 2001.05
    -
    2002.05

    慶應義塾大学医学部

  • 2002.06
    -
    2003.05

    東京都済生会中央病院

  • 2003.06
    -
    2004.05

    東京医科大学医学科

  • 2004.06
    -
    2007.04

    大田原赤十字病院

  • 2005.05
    -
    2006.05

    慶應義塾大学医学部

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 1995.04
    -
    2001.03

    慶應義塾大学, 医学部

    University, Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • Doctor of Medical Science, Keio University, Dissertation, 2019.03

    Establishment of the optimal follow-up schedule after radical prostatectomy

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 医師免許, 2001.05

  • 日本泌尿器科学会専門医, 2006.04

  • 日本癌治療認定医機構認定医, 2011.04

  • 日本泌尿器科学会指導医, 2011.04

  • 泌尿器腹腔鏡技術認定医, 2012.04

display all >>

Page Top ▲
 

Research Keywords 【 Display / hide 】

  • Prostate cancer

  • Urothelical cancer

  • Soft tissue sarcoma

Page Top ▲
 

Papers 【 Display / hide 】

  • Anemia in patients ≥ 75 years with metastatic clear cell renal cell carcinoma: an important poor prognostic factor in the international metastatic renal cell carcinoma database consortium model

    Mizuno R., Yasumizu Y., Tanaka N., Takeda T., Morita S., Matsumoto K., Kosaka T., Asanuma H., Oya M.

    BMC Urology (BMC Urology)  24 ( 1 )  2024.12

    　View Summary

    Background: Due to an increase in life expectancy, the incidence of metastatic renal cell carcinoma (mRCC) in patients aged ≥75 years has been increasing. In this study we investigated the characteristics before treatment and the outcomes of systemic therapies for patients aged ≥75 years with mRCC and compared the results with those for patients aged < 75 years in order to determine whether differences in age influenced survival. Methods: A total of 206 consecutive Japanese patients with mRCC, including 47 patients aged ≥75 years, who received systemic therapy were included. Clinical data from medical records were retrieved and analyzed retrospectively. Survival analyses were determined using a Kaplan–Meier method, and analyzed with a log-rank test. Results: Elderly patients categorized as favorable risk group based on the International Metastatic RCC Database Consortium (IMDC) stratification system were significantly lower. Among IMDC risk factors, the rate of anemia was significantly higher in elderly patients. No statistically significant benefit in progression free survival for first and second line treatment was observed, whereas improvements in overall survival as well as cancer specific survival were seen in patients aged < 75 years. Conclusions: For mRCC patients aged ≥75 years, a higher proportion of base line anemia, which resulted in higher rates of IMDC intermediate/poor risk, would be responsible for shorter OS/CSS. Furthermore, mRCC patients aged ≥75 years tend to receive BSC instead of second line active treatment. Overcoming under-treatment in elderly patients might help to prolong survival in mRCC.

  • Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy

    Saito T., Matsumoto K., Tanaka N., Fukumoto K., Yasumizu Y., Takeda T., Morita S., Kosaka T., Mizuno R., Asanuma H., Hara S., Oya M.

    International Urology and Nephrology (International Urology and Nephrology)  56 ( 1 ) 129 - 135 2024.01

    ISSN  03011623

    　View Summary

    Purpose: Several preoperative factors have been suggested to be risk factors of disease recurrence after radical cystectomy. There is no study focusing on the impact on prognosis of bladder tumor ureteral invasion in preoperative imaging. Methods: The study population consisted of 136 patients, all of whom underwent radical cystectomy during the period between 2007–2019. We excluded patients with concurrent or a history of upper tract urothelial carcinoma and who underwent radical cystectomy for other cancers or nononcologic reasons. The starting point of this study was the timing of neoadjuvant chemotherapy or radical cystectomy and the endpoint was the timing of disease recurrence. To identify the factors influencing recurrence, univariate and multivariate analyses were performed using the Cox proportional hazard model. Recurrence-free survival curves were constructed using the Kaplan–Meier method. Results: Ureteral invasion was observed in 20 (14.7%) patients. Disease recurrence was observed in 11 (55.0%) of 20 ureteral invasion positive patients and 35 (30.2%) of 116 ureteral invasion negative patients, respectively. In the ureteral invasion positive group, clinical T and N stage were higher and hydronephrosis were more common than in the ureteral invasion negative group. According to the multivariate analysis, ureteral invasion (hazard ratio: 2.307, p = 0.016) and clinical N stage ≥ 1 (hazard ratio: 2.140, p = 0.028) were independent risk factors for postoperative recurrence. In the ureteral invasion positive group, more local recurrences were observed. Conclusion: This study suggested that ureteral invasion in preoperative imaging is a significant risk factor for postoperative recurrence.

  • Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel

    Fujiwara S., Kosaka T., Nishimoto Y., Kamisawa K., Watanabe K., Baba Y., Takeda T., Matsumoto K., Oya M.

    Prostate (Prostate)  84 ( 1 ) 25 - 31 2024.01

    ISSN  02704137

    　View Summary

    Background: Serum testosterone level is a potential prognostic marker for castration-resistant prostate cancer. However, its role as a prognostic marker in cabazitaxel chemotherapy remains unclear. This study aimed to elucidate the clinical significance of serum testosterone levels before cabazitaxel chemotherapy. Methods: This single-institution, retrospective study included 47 patients with metastatic castration-resistant prostate cancer (mCRPC) who received cabazitaxel therapy. Serum testosterone levels were measured before the initiation of cabazitaxel therapy. Results: Progression-free survival and overall survival (OS) were not significantly different between patients with high and low serum testosterone levels. Analysis of patients aged <70 years revealed that those with high serum testosterone levels (total testosterone level > 0.055 ng/mL) had significantly longer OS than those with low serum testosterone levels (total testosterone level < 0.055 ng/mL, p = 0.012). Multivariate analysis revealed that low serum testosterone levels (hazard ratio [HR] = 11.874, 95% confidence interval [CI] 2.076–67.953, p = 0.005) and high prostate-specific antigen levels (HR = 18.051, 95% CI 2.462–132.347, p = 0.004) in the pretreatment phase were independent prognostic factors for OS in patients receiving cabazitaxel therapy. Conclusions: Serum testosterone level may be a prognostic marker for cabazitaxel therapy in patients with mCRPC who are younger than 70 years, and high serum testosterone levels may lead to longer survival.

  • ASO Visual Abstract: Long-Term Prognosis and Treatment Strategy of Persistent PSA After Radical Prostatectomy

    Komori T., Matsumoto K., Kosaka T., Takeda T., Kamitani R., Yasumizu Y., Tanaka N., Morita S., Mizuno R., Asanuma H., Oya M.

    Annals of surgical oncology (Annals of surgical oncology)  30 ( 11 )  2023.10

  • Long-Term Prognosis and Treatment Strategy of Persistent PSA After Radical Prostatectomy

    Komori T., Matsumoto K., Kosaka T., Takeda T., Kamitani R., Yasumizu Y., Tanaka N., Morita S., Mizuno R., Asanuma H., Oya M.

    Annals of Surgical Oncology (Annals of Surgical Oncology)  30 ( 11 ) 6936 - 6942 2023.10

    ISSN  10689265

    　View Summary

    Purpose: Prostate-specific antigen (PSA) is thought to be undetectable (< 0.1 ng/mL) after radical prostatectomy (RP), and persistent PSA (≥ 0.1 ng/mL) is considered a failure of curative treatment. Materials and Methods: The study population consisted of 135 patients, all of whom underwent RP for localized prostate cancer, and developed persistent PSA. We set the starting point at the timing of RP, and the endpoints were the development of castration-resistant prostate cancer (CRPC) and cancer-specific survival. Results: Salvage radiation therapy (RT) and androgen deprivation therapy (ADT) were performed in 53 (39.3%) and 64 (47.4%) patients, respectively. Eighteen (13.3%) patients didn't receive any salvage treatment. During the median follow-up of 10.1 years, CRPC was observed in 23 patients, and 6 patients died due to prostate cancer. Kaplan-Meier curves demonstrated the 15-year CRPC-free and cancer-specific survivals were 79.5% and 92.7%, respectively. Cox multivariate analysis demonstrated that seminal vesicle invasion (SVI) (p = 0.007) and nadir PSA ≥1.0 ng/mL (p = 0.002) were independent risk factors for CRPC. Salvage RT demonstrated better cancer control (the 10-and 15-year CRPC-free survival was 94.1% and 94.1%) compared to ADT (75.9% and 58.5%, p = 0.017) after 1:1 propensity score matching. Conclusions: SVI and nadir PSA ≥1.0 ng/mL are independent risk factors for CRPC in patients with persistent PSA after RP. Salvage RT is considered to be the optimal treatment for this condition.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 高齢者の表在性膀胱癌間じゃに対するBCG膀注の再発予防効果についての検討

    弓削和之、菊地栄次、松本一宏、宮嶋　哲、中川　健、大東貴志、中島　淳、大家基嗣

    第96回日本泌尿器科学会総会 (横浜) , 

    2008.04
    , 

    Oral presentation (general)

  • 放射線照射後の膀胱穿孔に伴う急性腎不全の一例

    Matsumoto Kazuhiro

    日本泌尿器科学会東京地方会 (第582回) , 

    2006.06
    , 

    Oral presentation (general)

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 酸化ストレス応答に着目した間質性膀胱炎の発症メカニズム解明と治療法の開発

    2021.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • ドラッグ・リポジショニングを用いた、膀胱癌に対する抗癌剤注入療法の効果増強

    2018.09
    -
    2019.08

    第一三共奨学寄付プログラム, No Setting

  • ドラッグ・リポジショニングを用いた、筋層非浸潤性膀胱癌の抗癌剤注入療法耐性の克服

    2018.08
    -
    2019.07

    サノフィ・ジャパングループ教育研究助成, No Setting

  • ドラッグ・リポジショニングを用いた、筋層非浸潤性膀胱癌に対する新規膀胱内注入療法の開発

    2018.05
    -
    2019.04

    慶應義塾大学学事振興資金, No Setting

  • ドラッグ・リポジショニングを用いた、膀胱癌に対する新規膀胱内注入療法

    2018.04
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research (C), Principal investigator

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • 慶應義塾大学医学部三四会奨励賞

    2015.06

  • IJU Reviewers of the Year 2013

    2014.04

  • 第49回癌治療学会優秀演題賞

    2011.11

  • 第45回癌治療学会優秀演題賞

    2007.10

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, UROLOGY

    2025

  • LECTURE SERIES, UROLOGY

    2024

  • LECTURE SERIES, UROLOGY

    2023

  • LECTURE SERIES, UROLOGY

    2022

  • LECTURE SERIES, UROLOGY

    2021

display all >>

Page Top ▲